Mild Cognitive Impariment is Early-Stage Alzheimer Disease
Arch Neurol 63:15-16, Morris,J.C., 2006
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Risk Factors for Variant Creutzfeldt-Jakob Disease: A Case-Control Study
Ann Neurol 59:111-120, Ward,H.J.T.,et al, 2006
Incidence and Causes of Nondegenerative Nonvascular Dementia
Arch Neurol 63:218-221, Knopman,D.S.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006
The Natural History of Primary Lateral Sclerosis
Neurol 66:647-653, Gordon,P.H.,et al, 2006
Delirium in Older Persons
NEJM 354:1157-1165, Inouye,S.K., 2006
Valproic Acid Adjunctive Therapy for HIV-Associated Cognitive Impairment: A First Report
Neurol 66:919-921, Schifitto,G.,et al, 2006
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Donepezil in Patients with Severe Alzheimers Disease: Double-Blind, Parallel-Group, Placebo-Controlled Study
Lancet 367:1057-1065,1031, Winblad,B.,et al, 2006
Ruptured Cavernous Sinus Aneurysms Causing Carotid Cavernous Fistula: Incidence, Clinical Presentation, Treatment, and Outcome
AJNR 27:185-189, van Rooij, W.J.,et al, 2006
Psychiatric Manifestations of Creutzfeldt-Jakob Disease: A 25-Year Analysis
J Neuropsychiatry Clin Neurosci 17:489-495, Wall,C.A.,et al, 2005
Serial Diffusion-Weighted MRI of Creutzfeldt-Jakob Disease
AJR 184:560-566, Ukisu,R.,et al, 2005
Pallidorecticular Damage in acute Carbon Monoxide Poisoning: Diffusion-Weighted MR Imaging Findings
AJNR 26:1845-1848, Kinoshita,T.,et al, 2005
Delusions and Hallucinations in Dementia with Lewy Bodies: Worsening with Memantine
Neurol 65:481-482, Ridha,B.H.,et al, 2005
Creutzfeldt-Jakob Disease Mimicking Radiologic Posterior Reversible Leukoencephalopathy
Neurol 65:329, Sibon,I.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohns Disease
NEJM 353:362-368, Van Assche,G.,et al, 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Headache as the Only Neurological Sign of Cerebral Venous Thrombosis:A Series of 17 Cases
JNNP 76:1084-1087,1043, Cumurciuc,R.,et al, 2005
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005
Global Prevalence of Dementia: A Delphi Consensus Study
Lancet 366:2112-2117, Ferri,C.P.,et al, 2005
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 65:1863-1872, McKeith,I.G.,et al, 2005
Update on Primary Central Nervous System Lymphoma
Curr Opin Neurol 18:645-653, Plotkin,S.R., 2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Arch Neurol 62:1595-1600, Omuro,A.M.P.,et al, 2005
Sustained Recovery of Progressive Multifocal Leukoencephalopathy After Treatment with IL-2
Neurol 65:1510, Kunschner,L. &Scott,T.F., 2005
Neurological and Neuromuscular Disease as a Risk Factor for Respiratory Failure in Children Hospitalized With Influenza Infection
JAMA 294:2188-2194, Keren,R.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Carbamazepine Encephalopathy Masquerading as Creutzfeldt-Jakob Disease
Neurol 65:650-651, Horvath,J.,et al, 2005
Neuropathology of Dementia in Parkinsons Disease: A Prospective, Community-Based Study
Ann Neurol 58:773-776,663, Aarsland,D.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005
Hemiplegic ALS:Mills Syndrome
Neurol 64:1984-1985, Rajabally,Y.A.,et al, 2005
Frontotemporal Lobar Degeneration
Arch Neurol 62:925-930, Johnson,J.K.,et al, 2005
Diffusion-Weighted and Fluid-Attenuated Inversion Recovery Imaging in Creutzfeldt-Jakob Disease:High Sensitivity and Specificity for Diagnosis
AJNR 26:1551-1562, Young,G.S.,et al, 2005
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
New and Reliable MRI Diagnosis for Progressive Supranuclear Palsy
Neurol 64:2050-2055, Oba,H.,et al, 2005
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005
Different Patterns of Magnetic Resonance Imaging Atrophy for Frontotemporal Lobar Degeneration Syndromes
Arch Neurol 62:1106-1110, Short,R.A.,et al, 2005
The Genetic Causes of Basal Ganglia Calcification, Dementia, and Bone Cysts
Neurol 64:1502-1507, Klunemann,H.H.,et al, 2005
Atypical PML Leading to a Diagnosis of Common Variable Immunodeficiency
Neurol 64:1661, Snyder,M.D.,et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005